Celltex is looking into using stem cells to treat COVID-19, and the Houston biotech company just got the green light to go to trials. Photo courtesy of Celltex

A Houston-based biotech company announced last week that it has gotten the approval it was seeking from the U.S. Food and Drug Administration to continue testing its COVID-19 treatment that uses stem cells.

Celltex has received approval from its Investigational New Drug application, or IND, to look into stem cells — specifically Autologous Adipose Tissue-Derived Mesenchymal Stem Cells, or AdMSCs — and their effect on COVID-19 patients.

"The FDA's approval of our IND is not only a critical milestone for Celltex, but also for everyone who has been affected by COVID-19," says David G. Eller, Celltex chairman and CEO. "I am optimistic that our findings will result in favorable outcomes that will improve lives today and for generations to come."

Celltex has been in the stem cell business for nearly a decade and has treated patients with debilitating diseases like multiple sclerosis, Parkinson's, rheumatoid arthritis, and more. Eller says he's been considering how Mesenchymal Stem Cells, or MSCs, could be used amid the pandemic.

"Throughout the entire pandemic, MSCs have shown promise for combatting symptoms and complications associated with COVID-19, and as the nation's leading commercial MSC banking and technology company, Celltex has the unique ability to transition these initial findings into a clinical trial," Eller says.

The FDA clearance will allow for a phase two trial "that will evaluate the safety and prophylactic efficacy of AdMSCs against COVID-19," according to the release. There will be 200 patients across multiple centers that will be involved in the placebo-controlled study.

Celltex offices out of the Galleria area and has laboratory operations of its wholly-owned Mexican subsidiary are located in Hospital Galenia in Cancún, Quintana Roo, Mexico. Last year, Celltex planned an expansion into Saudi Arabia and also has a presence in Europe.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.


Saudi Arabian representatives met at Houston-based Celltex Therapeutics Corp.'s office earlier this month to finalize a memorandum of understanding. Courtesy of Celltex

Houston biotech company plans expansion into Saudi Arabian market

On the move

A Houston company that uses stem cell technology to treat patients suffering from degenerative diseases is taking its patented technology to another continent.

Celltex Therapeutics Corp. has entered a memorandum of understanding with Saudi Arabia's Research Products Development Company. As a part of the partnership solidified by the MOU, Celltex will open an office in Riyadh, Saudi Arabia, later this year. The new office will aid the commercialization of Celltex's technology and expand the company's presence to Saudi Arabia.

"We are honored to forge a relationship with Saudi Arabia," says David G. Eller, CEO and chairman of Celltex, in a release. "Our collaboration with this first-rate global cohort furthers our commitment to initiating breakthroughs in regenerative medicine, and our presence in Riyadh will further expand our opportunities to improve the quality of life of those in need."

The MOU is a part of the country's effort to diversify the economy that's been dominated by oil and gas, the release says. As a part of Saudi Arabia's National Industrial Development and Logistic Program, Celltex and other United States companies were invited to Riyadh to sign MOUs in January, which resulted in billions of dollars in Saudi investment, per the release.

On February 4, the two parties reconvened at Celltex's office in Houston. The group included top Saudi dignitaries, Abdulmohsen Almajnouni, CEO of RPDC, as well as others.

"We are excited to explore business opportunities with Celltex, a biotechnology company with the innovative proprietary technology, patents and know-how for the cultivation and therapeutic application of stem cells," Almajnouni says in the release.

Celltex currently extracts patients' stem cells at various partner facilities across the United States, but implementation happens at a hospital in Mexico, due to FDA regulations and red tap. However, Eller doesn't foresee this being the process forever.

"We have very good relations with the US FDA," he says in an InnovationMap article. "They are very interested in what we know. Our approach is really is very progressive and we've grown every year."

The company's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

From a locally sourced meal service company to stem cell research and a balance measuring device, this week's innovators are ones to know in the health industry. Courtesy photos

3 Houston health-focused innovators to know this week

Who's who

More and more Americans are focusing on their health, from eating right to experimenting with new treatments or devices. These three Houston innovators are riding the coattails of this health-focused movement with their startups. With advances in technology and the movement only growing faster and faster, you'd better keep your eye on these Houston innovators.

Marla Murphy, founder of The Blonde Pantry

Courtesy of The Blonde Pantry

Marla Murphy didn't feel like she was doing enough to promote health and wellness with her platform, The Blonde Pantry. So, she expanded it to incorporate locally sourced produce and easy-to-make recipes she gets ready every weekend to deliver to her members by Monday.

"It's not about selling meals and moving on, I want this to be a lifestyle company that is really founded and has deep roots in Houston," says Murphy in a InnovationMap story.

Murphy tells InnovationMap that in the next year she hopes to expand into the retail space and find a bigger commercial kitchen to function as their own. She also hopes to partner with companies outside of food and continue to nourish lives in someway.

David Eller, chairman, co-founder and CEO of Celltex

Courtesy of Celltex

Stem cell treatment is personal to David Eller, chairman, co-founder and CEO of Celltex. Eller had the treatment in hopes of resolving pain from a college football injury.

"I would go to work and put four to six Advil in my pocket," Eller says in an InnovationMap story about Celltex's technology. Within months, he stopped needing those pills.

Houston-based Celltex tracks its progress with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

Katharine Forth, founder and CEO of Zibrio

Courtesy of Zibrio

Katharine Forth has used a technology she developed with her colleague at NASA to measure balance in astronauts to create a device that any terrestrial human can now use from the comfort of their own homes.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says in an InnovationMap article about Zibrio, The Balance Company. Zibrio, The Balance Company.

Zibrio is now a finalist for the 2019 SXSW Pitch in the health and wearables category and will take its balance technology to the stage in March.

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

Houston company uses stem cell technology to treat patients suffering from degenerative diseases

Regeneration nation

The medical community has former governor Rick Perry to thank for a major stride in regenerative medicine.

"He had just gotten elected for the last time and he wanted to leave a legacy. He was tired of people going to Japan or Germany when they needed stem cells," recalls David Eller, chairman, co-founder and CEO of Celltex.

That was 2011, the year that the former president of Dupont Pharmeceuticals-Europe and orthopedic surgeon Dr. Stanley Jones incorporated as Celltex. Perry got the law passed to make it legal to harvest his stem cells, and Jones implanted them while the governor was under the knife for a spinal fusion surgery.

Perry resigned from the Celltex board in 2017, but the truth is, the company no longer needed his clout. Just a year after its debut, the company had in excess of 200 clients, each paying a banking enrollment fee of $6,500. Now, there are close to 1,300.

From research to recovery
Eller is originally from Houston, and he says his hometown is the ideal home base for the company, with its access to the world's largest medical center. The Galleria-area office and lab employ 35 people, with about 50 workers worldwide.

Close to the same time that his friend Perry received his stem cells, Eller also had the treatment in hopes of resolving pain from a college football injury.

"I would go to work and put four to six Advil in my pocket," the CEO recalls.

Within months, all of them remained in his pocket.

But others have had even more dramatic results. Celltex checks in with patients three, six and nine months after their treatments to find out how they're doing. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

Implementation and the FDA
Celltex's chief scientific officer, Dr. Jane Young, co-authored a study of two severe juvenile rheumatoid arthritis patients whose conditions didn't respond to standard treatments. After trying stem cells, both reported marked improvement in autonomic nervous system and immune function.

Stem cells are gathered through a patient's fat, which can be extracted at any of the 80 facilities around the country that partner with Celltex. The fat is processed at the Houston lab, where processing takes 30 to 35 days.

"We have 15 billion cells in process each day," says Erik Eller, the company's vice president of operations, clarifying that some clients' cells grow faster than others'.

It takes 14 days to come out of cryostasis and leave the lab. From there, the stem cells travel to Hospital Galenia in Cancun, Mexico for implantation, since the FDA categorizes stem cells as a drug if they have expanded as they do at Celltex. That means that a patient cannot use his own stem cells in the United States without a clinical trial. To circumnavigate the red tape, Celltex has simply partnered with the luxurious Mexican hospital.

This is currently the company's biggest challenge, says David Eller, but one he expects to overcome.

"We have very good relations with the US FDA," he says. "They are very interested in what we know. Our approach is really is very progressive and we've grown every year."

Ultimately, Eller hopes to be able to implant stem cells in the United States. But the company's foreign growth is a good start. Celltex is now operating in the Bahamas and is hoping to add Australian extraction facilities sometime this year. They are also in negotiations with a team from Saudi Arabia interested in expanding Celltex to the Middle East.

Other goals for Celltex include improvements both in the realms of sales and revenue and streamlining and improving the safety and efficacy of treatment. Research collaborations with Baylor College of Medicine and Texas A&M will help with the company's medical credibility. This all may help to convince the FDA to allow the Celltex to get a biologics license, the final proof that it is not a drug company. But no matter how it's categorized, Celltex is growing exponentially as its cells.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Fast-growing Houston tech firm leads dozens of local companies on Inc. 5000

growth report

Dozens of Houston-area businesses appear in this year’s Inc. 5000 ranking of the 5,000 fastest-growing private companies in the U.S., with a security software provider capturing the region’s No. 1 spot on the list.

Landing at No. 29 nationally and No. 1 in the software category, the top-ranked Houston-area private company is Houston-based Action1. The company recorded median revenue growth of 7,188 percent from 2021 to 2024, according to the Inc. 5000.

It’s the first appearance on the Inc. 5000 list for Action1, founded in 2018.

Action1 produces patch management software. A patch, or fix, quickly repairs software to resolve functionality problems, improve security or add features, according to TechTarget.

“Modern organizations understand that proactive patch management is essential to staying ahead of today’s rapidly evolving threat landscape,” Mike Walters, co-founder and president of Action1, said in a news release. “Our continued hypergrowth reflects the increased demand for enterprise cybersecurity innovation. You can’t be just powerful and secure — you must also be simple to deploy and scale and cost-effective.”

Below are the Houston-area businesses that earned a ranking among the top 1,000 companies, including their industries and their three-year growth rate. To see the other Houston-area companies in the Inc. 5000, visit inc.com/inc5000/2025.

  • No. 29 Houston-based Action1, software (7,188 percent)
  • No. 49 Spring-based Bogey Bros Golf, retail (5,540 percent)
  • No. 84 Houston-based Turtlebox Audio, consumer products (3,818 percent)
  • No. 87 The Woodlands-based Allied Wealth, financial services (3,796 percent)
  • No. 319 Houston-based Strategic Office Support, business products and services (1,228 percent)
  • No. 324 Houston-based Novo Communications, security (1,212 percent)
  • No. 363 Houston-based OptiSigns, software (1,101 percent)
  • No. 385 Houston-based Cart.com, business products and services (1,053 percent)
  • No. 421 Houston-based Sydecar, financial services (962 percent)
  • No. 471 The Woodlands-based Acuity Technology Partners, IT services (869 percent)
  • No. 577 Stafford-based Dahnani Private Equity Group, real estate (718 percent)
  • No. 706 Houston-based Why Not Natural, consumer products (585 percent)
  • No. 709 Stafford-based Signarama Sugar Land, manufacturing (584 percent)
  • No. 744 Houston-based FINBOA, software (557 percent)
  • No. 747 Houston-based Amundson Group, human resources (557 percent)
  • No. 793 Houston-based Field Industries, manufacturing (533 percent)
  • No. 957 Friendswood-based Good Ranchers, food and beverage (448 percent)
  • No. 999 Houston-based ARIA Signs & Design, business products and services (428 percent)

Houston universities climb the ranks on annual list of most patents issued

top 100

The University of Houston and Rice University have claimed spots on the National Academy of Inventor's Top 100 U.S. Universities Granted Utility Patents.

The list is based on data obtained from the U.S. Patent and Trademark Office and ranks U.S. academic institutions that are advancing innovation by the number of utility patents issued in the prior year.

Utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights to produce and use their technology. The universities ranked on the list collectively hold nearly 6,500 patents.

“In the ever-evolving innovation landscape, it is imperative that the U.S. is remaining competitive and at the forefront of today’s emerging research and technologies,” Paul R. Sanberg, president of the NAI, said in a news release. “Ensuring the security of intellectual property through patenting is a crucial component to this and allows those innovations to be effectively moved to market, where they can create valuable societal and economic impact. The Top 100 U.S. list celebrates U.S. universities and their inventive staff and faculty for their dedication in ensuring their innovations and IP are protected.”

The University of Houston System came in at No. 62 with 34 patents, and Rice University claimed the No. 68 spot with 30 patents.

Both universities climbed up the rankings this year. Last year, UH was ranked No. 63 with 27 patents. Rice climbed an impressive 26 spots this year, after ranking No. 94 with 14 patents issued in 2023.

“Granted U.S. utility patents can tremendously help in commercializing the technologies covered by such patents by attracting industry investment and commercial partners on a global level,” Neha Malik, assistant director for intellectual property management in Rice's Office of Technology Transfer, said in a release. “Advancing in this list memorializes Rice’s commitment to support research programs of Rice faculty by generating a path for the university to bring its research to the marketplace.”

Other Texas universities on the list include:

  • No. 3 University of Texas System (234 patents)
  • No. 35 The Texas A&M System (61 patents)
  • No. 73 Texas Tech University System (25 patents)
  • No. 80 Baylor University (20 patents)

The University of California (540 patents) claimed the No. 1 spot again this year, followed by the Massachusetts Institute of Technology (295 patents), which also placed second for 2024.

First large-scale affordable housing project of 3D-printed homes rises in Houston

Building Blocks

What’s being promoted as the world’s first large-scale affordable housing development built using 3D technology is taking shape in Houston.

Houston-based 3D construction company HiveASMBLD has teamed up with Houston-based Cole Klein Builders and the City of Houston on the Zuri Gardens project. Located near Hobby Airport on Martindale Road, the first 3D-printed home at Zuri Gardens is set to be completed in October.

“Zuri Gardens was born from the frustration of watching hardworking families get priced out of safe, resilient housing. We knew there had to be a better way — and with this project, we’re proving that there is,” says Vanessa Cole, co-founder of Cole Klein Builders.

“By combining visionary design, advanced construction technology, and powerful partnerships, we’re building more than just homes — we’re creating a blueprint for the future of equitable homeownership in Houston and beyond.”

The development is being created for households earning up to 120 percent of the median income in the Houston metro area. For a four-member household in the Houston area, the 120 percent limit in 2025 is $121,300, as set by the U.S. Department of Housing and Urban Development (HUD).

The 13-acre Zuri Gardens development will feature 80 energy-efficient homes averaging 1,360 square feet. Prices will be in the mid to high $200s. The homes will qualify for up to $125,000 in down payment assistance from the City of Houston.

HiveASMBLD will print two different home designs, each with two-bedroom and two-and-a-half bathroom configurations, along with an office/flex space and a covered patio.

Zuri Gardens home model Houston Courtesy rendering

“The community we envision for Zuri Gardens is modern, safe, and one that residents will be proud to call home. When completed using HiveASMBLD’s innovative technology, this 3D-printed multifamily community will exemplify the future of residential affordable living,” says Timothy Lankau, founder and co-CEO of HiveASMBLD.

Developments like Zuri Gardens are popping up around the country.

“3D-printed homes are revolutionizing the construction industry by making home builds faster, cheaper, and more sustainable,” according to The Zebra, an Austin-based insurance marketplace. “In less than 24 hours, 3D printers can print the foundation and walls for a small home at a fraction of the cost of typical construction.”

U.S. News & World Report explains that unlike a traditional home, a 3D-printed home is printed in place, “just like you’d print a knickknack on your home 3D printer. Layer by layer, proprietary concrete blends are used to build the wall systems of the home in any type of design that a builder can imagine.”

Texas is home to several trailblazing 3D-printed projects.

In the U.S., the first 3D-printed home was built in 2018 in Austin, and the first 3D-printed multistory home was completed in 2023 in Harris County’s Spring Branch neighborhood. Meanwhile, the world’s largest neighborhood of 3D-printed homes is located in the Austin suburb of Georgetown.

Grand View Research predicts the global market for 3D-printed construction will approach $4.2 billion by 2030.

---

This article originally appeared on CultureMap.com.